Rosetta Genomics (ROSG) Continues Recent Surge
Tweet Send to a Friend
Up)
Rosetta Genomics, Ltd. (Nasdaq: ROSG) is seeing sharp upside today. Shares are up 16 percent currently to $8.62.
Shares have been en fuego since May 16th when the company announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets assay, informed Rosetta that it plans to cover this assay for all Medicare beneficiaries.
A direct equity offering following that huge May 16th pop slowed the stock down for a day, but it has been all uphill since.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares have been en fuego since May 16th when the company announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets assay, informed Rosetta that it plans to cover this assay for all Medicare beneficiaries.
A direct equity offering following that huge May 16th pop slowed the stock down for a day, but it has been all uphill since.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Rosetta Genomics (ROSG) Sees Mid-Day Upside
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Marketo (MKTO) IPO Opens 54% Higher
Create E-mail Alert Related Categories
Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
